{"id":991164,"date":"2026-08-06T08:31:46","date_gmt":"2026-08-06T12:31:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evolent-announces-second-quarter-2026-results\/"},"modified":"2026-08-06T08:31:46","modified_gmt":"2026-08-06T12:31:46","slug":"evolent-announces-second-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evolent-announces-second-quarter-2026-results\/","title":{"rendered":"Evolent Announces Second Quarter 2026 Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WASHINGTON<\/span>, Aug. 6, 2026<\/span> \/PRNewswire\/ — Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June\u00a030, 2026.<\/p>\n

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure.”<\/p>\n

Mario Ramos, Chief Financial Officer of Evolent stated, “Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility.”<\/p>\n

Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n \n <\/td>\n\n

\n
\n For the Three Months<\/b>
\n
\n Ended June 30,<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n
\n 2026<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n
\n 2025<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Financial Results:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n Revenue<\/span>\n <\/p>\n<\/td>\n

\n

\n $\u00a0\u00a0\u00a0\u00a0\u00a0652,520<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $\u00a0 \u00a0 \u00a0 444,328<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Net loss attributable to common shareholders of Evolent Health, Inc.<\/span>\n <\/p>\n<\/td>\n

\n

\n $\u00a0 \u00a0 \u00a0 (28,364)<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $\u00a0 \u00a0 \u00a0 \u00a0(51,090)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Net loss margin<\/span>\n <\/p>\n<\/td>\n

\n

\n (4.3)\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n (11.5)\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Adjusted EBITDA<\/span>\n <\/p>\n<\/td>\n

\n

\n $\u00a0 \u00a0 \u00a0 \u00a028,050<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $\u00a0 \u00a0 \u00a0 \u00a0 37,547<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Adjusted EBITDA Margin<\/span>\n <\/p>\n<\/td>\n

\n

\n 4.3\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 8.5\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n
\n Average Lives on Platform\/Cases by Product Type<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n Performance Suite<\/span>\n <\/p>\n<\/td>\n

\n

\n 6,715<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 6,490<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Specialty Technology and Services Suite<\/span>\n <\/p>\n<\/td>\n

\n

\n 75,641<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 77,019<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Administrative Services<\/span>\n <\/p>\n<\/td>\n

\n

\n 1,189<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 1,231<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Cases<\/span>\n <\/p>\n<\/td>\n

\n

\n 12<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 13<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n Average Unique Members<\/span>\n <\/p>\n<\/td>\n

\n

\n 39,956<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 40,201<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n
\n Average PMPM Fees\/ Revenue per Case by Product Type<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n Performance Suite<\/span>\n <\/p>\n<\/td>\n

\n

\n $\u00a0 \u00a0 \u00a0 \u00a0 \u00a024.05<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a013.76<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Specialty Technology and Services Suite<\/span>\n <\/p>\n<\/td>\n

\n

\n 0.34<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 0.35<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Administrative Services<\/span>\n <\/p>\n<\/td>\n

\n

\n 13.46<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 15.13<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Cases<\/span>\n <\/p>\n<\/td>\n

\n

\n 3,608<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 2,969<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n Medical Expense Ratio<\/span>\n <\/p>\n<\/td>\n

\n

\n 95.3\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 80.0\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Medical Expense Ratio excluding Evolent Care Partners<\/span>\n <\/p>\n<\/td>\n

\n

\n 95.3\u00a0%<\/span>\n <\/p>\n<\/td>\n

\n \n <\/td>\n\n

\n 84.9\u00a0%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

The rising medical costs impacting health plans continue to drive robust demand for Evolent’s complex specialty care solutions.<\/p>\n

Evolent has two partnership announcements, bringing the year-to-date total to four:<\/p>\n